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In psoriatic lesions, epidermal keratinocytes overex-
press vascular endothelial growth factor/vascular 
permeability factor (VEGF/VPF) and transforming 
growth factor alpha (TGF-ll'). TGF-ll' has been shown 
to induce VEGF/VPF in normal human epidermal 
keratinocytes i11 vitro. By using a 19-iller antisense 
phosphorothioate oligodeoxynucleotide (PS-ODN) 
complementary to bases 6 -24 relative to the transla-
tional start site of the VEGF/VPF mRNA, the control 
sense and mismatched PS-ODNs, we examined mod-
ulation of VEGF/VPF induction by TGF-ll' ill I1itl'O. 
Normal human epidermal keratinocytes were treated 
with PS-ODNs and Lipofectin for 8 h prior to the 
V ascular endothelial g rowth f.~cto r/vascular permc-ability factor (VEGF/VPF) has been shown to playa major role in discases assoc iated with increased vascular pe rmea bili ty and ang iogenes is. Overex-pression of VEGF/VPF is cvident in many patho-
logic skin disorde rs, in particular, psoriasis (Detmar el ai, 1994), 
delayed hyp ersensitiv ity reactions (Brown et ai, 1995b), and in some 
buUous di seases with subepidermal blister formation (Brown el ai, 
1995a). 
VEGF/VPF is a homodimeric 36-46 kDa protein offour isoforms 
generated by alternate splicing m cch anism s (Ferrara el ai, 1991; 
T ischer et ai, 1991). T h c 121-165 amino acid isofonns are secreted, 
w hereas the 189-206 am.ino acid isoforms appear to remain cell 
associated (Park cI ai, 1993 ) . Bal laul1 el al (1995) alld Detmar el al 
(1995) ha ve shown that the three major spliced forms of V EGFI 
VPF (189, 165, and 121 amino acids) are produced by primary 
cu ltures of human epide rmal kcratiuocytes. T he VEGF/VPF se-
creted by keratinocytes is bi o log ically active, as it ca uscs a mito -
genic response in cultu red human de rmal microvascular endothelial 
cells (Detmal" e/ ai, 1995). 
!II Ilirl O, overexpression of VEGF/VPF is o bserved in psoriati c 
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addition ofTGF-ll'. Inhibition was assayed at the level 
of secreted protein by capture ELISA and mRNA 
expression was assayed by Northern blot analysis. 
The anti-sense PS-ODN was capable of inhibiting 
VEGF/VPF RNA and protein to near-basal levels. 
This inhibition was concentration dependent. No 
effect was observed with the sense or mismatch con-
trol PS-ODNs. These studies suggest that antisense 
oligonucleotide technology lIlay be a potential ther-
apy for the inhibition of angiogenesis associated with 
certain skin disorders such as psoriasis. ] I1west Del'-
matol 108:523-526, 1997 
skin . The two receptors for VEGF/VPF, KDR and At- l (Tcrman el 
ai, 1992; dc Vries el (/1,1992), are also overexpressed in unde rlying 
papillary de rm al microvascular endothe lial cells (Detmar et ai, 
1994). 1n additi o n , lesional psoriatic keratinocytes express e levated 
levels of transforming growth factor- a (TGF-a) (Elder el ai, 1989), 
a known inducer ofVEGF/ VJ>F expression in primary keratinocyte 
cultures (Dctmar et ai, 1994) . A decrease ill TGF-a has been 
observed upon clearance of pso riasis after various treatment regi-
m cns (Watts e/ ai, 1994), and there is evidcnce that VEGF/ VPF 
levels decreasc during su ccessful treatment of psoriasis (Detmar and 
Watts, unpublished resu lts). 
T he work presented he rein demonstrates dowmegulation of 
VEGF/VPF in a TGF-a-indl1cible keratinocyte system using anti-
sense o ligonucleotide technology. T lus rep ort suggests the poten-
tial clin.ica l application of o ligodeoxynl1cleotides as a topica l treat-
m ent of skin disorders charactel'ized by overexprcss io n of VEGFI 
VPF, enh anced angiogen es is, and/or mic rovascular permeability. 
MATEIUALS AND METHODS 
Reagents TGF-O', Trizo l Reagent, and Lipofectin were pmchased from 
GIBCO BIU (Gaithersburg. MD). TGF- O' at 100 ng/ml and Lipofectin at 5 
J.Lg/ ml were used in all experiments. Affiniry-purified rabbit anti-human 
VEGF/VPF polyclonal antibody was a gift from Dr. Donald Senger of Beth 
Israel Hospital, Boston. MA. 
Cell Culture Normal hUlllan epidermal kcratinocytes (NHEKs) were 
purchased £i'om Clonetics (San Diego, CAl and grown as rccommended in 
keratinocyte growth medium. Cells for all experiments were used at pass:lge 
2 or 3 and cu lturcd in a humidified incuba tor with 1.0% CO~/90% air at 
37°C. For antiscnse tteamlCnt. the medium from conAuent cultures was 
aspirated and replaced with kcratinocyte basal medium (KBM) conta ining 
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Figure 1. Uptake of FITC-ODN i. enhanced by the addition of 
Lipofectin ill NHEKs. Keratinocytes were treated for 8 h w ith F1TC-
ODN in the presence or absence of Lipofectin (LFT). The cell s we re 
t"ypsinizcd and analyzed by Aow cytometry. The greatest increase in 
Auorescence was observed upon Lipofectin addition to the ce ll s. 'Values 
shown represcnt the mean of logaritlunic Auorescence values obtained in 
the count ,'erSIIS loga rithnlic channel histograill . 
Lipofectin followed by the add ition of phosphorothioate o ligodeoxyn.ucle-
otides (PS-ODNs) of the appropriate concentration. After 8 h tlw medium 
was replaced with KBM in the presence o r absence ofTGF-a. The medium 
was collected at 24 or 48 h after TGF-a addition and analyzed by 
enzyme-linked immunosorbent ass;,y (ELISA). Total RNA was harvested 
from tile cells and examined by northern blot analysis. 
Oligodeoxynucleotides PS-ODNs were synthesized by using phos-
phoramidite chemistry o n a Biosearch 8700 (Millipore, Bedford, MA) 
automatcd synthesizcr. T he fo llowing sequences we re used: antisense 
molecule 1-13 , 5'-CACCCAAGACAGCAGAAAG-3', and the control sense 
molecule H3S, 5'-CTTTCTGCTGTCTTGGGTG-3'; 5' I-bp mismatch 
(MM). 5' -CTCCCAAGACAGCAGAAAG-3'; 5' 2-bp MM, 5'-CTGC-
CAAGACAGCAGAAAG-3'; central (cen) 4-bp MM, 5'-CAC-
CCAACTCTCCAGAAAG-3'; 3' l-bp MM, 5'-CACCCAAGACAGCA-
GAATG-3'; 3' 2-bp MM, 5'-CACCCAAGACAGCAGATTG-3'. A 
Auorescein moiety was attached to the 5' end of the H3 PS-ODN for Aow 
cytometry expedments. All experiments were pcrformed with 0.5 f.LM 
oJigodeox)'nucleotides, unless otherwise stated. 
Flow Cytometry For uptake analysis, cells were grown in six-well plates 
in kcratinocytc growth ll1Cdiul"tl. ConAucnt c ultures w e re incubated in 
KBM with or witl10ut Auorescein isothiocyanate-Iabeled PS-ODN (FITC-
OON) in the absence or presencc of Lipofectin for 8 h . Cells were 
trypsinized, washed twice with phosphate-buffered salinc , and analyzed on 
Figure 2. Antisense PS-ODN (H3) 
inhibits VEGF/VPF protein produc-
tion induced by TGF-a. NHEKs were 
treated for 8 h w ith Lipofcctin with or 
withollt 0.5 /LM antisense and control 
PS-OONs (a) or a dose range of 1 f.LM to 
0.05 f.LM antisense (H3) or sense (H3S) 
PS-ODNs (b). The medium was replaced 
with KBM with or without TGF-a and 
anal),zed 48 h la ter for VEGF/VPF by a 
capture ELISA. T he untreated (UT) and 
TGF-a samples in (a) received no PS-
OON treatment. The UT sample received 
KBM only and shows the endogenous 
levels of VEGF/ VPF. (a) Effects of the 
antisense, sense, and five Itl.isnlatch (MM) 
control PS-OONs. (b) Samples arc ]-[3 
anti sense (IITJ) and H3S sense (_) PS-
OONs. All PS-OON-treated cells re-
ceived ICBM plus TGF-a. Data arc ex-
pressed as optica l density (0.0.) units at 
450 nm subtracting 0.0. units 620 nm for 
background. Error bars, SO (n = 3). 
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a Coulter Epics XL Aow cytometer (Hialeah, FL), gating on ti ve cells. 
Fluorescence was monitored at 488 nl11 wi til a 525-nl11 band pass filter. 
Human VEGF/VPF Capture ELISA Nunc Maxisorp 96-wcll plates 
were coated overnight at 4°C with anti-human VEGF/VPF monoclonal 
antibod), (R & 0 Systems. Minneapolis , MN) and blocked for 2 h with 2% 
normal human serum. Cell supernatants were added and incubated over-
night at 4°C. Plates were wash cd three times in 0.05% Tween20/ phosphate-
bufrcrcd sa line on a Dynatech (ChantiUy. V A) plate washer and au 
affinity-purified n,bbit anti-hun"111 VEGF/VPF polyclonal antibody (1.5 
f.Lg/ml) was added and allowed to incubate for 2 h at 3 rc. Plates were 
washed as described above and a 1:10,000 dilution of a horse radish 
peroxidase-conjugated goat anti-rabbit IgG secondary antibody (Kirkegaard 
and Perry, Ga ithersburg, MO) was added and allowed to incubate for 1 h at 
37°C. ELISA p lates were developcd by using the TMB MicroweU Permci-
dase Substrate System (Kirkegaard and Perry) and analyzed on a Ceres 900 
HDi plate reader (Biotek Instrulllents. Winooski. VT). 
Northern Blot Analysis RNA was preparcd using Trizol accord ing to 
manufacturer's directions. Total RNA was separated on a 1 % formaldehyde 
denaturing agarose gel (Ch0111 CZynski and Makey, 1994), transferred to 
Zeta-Probe (Bio-Rad, Hercules, CAl nylon membrane, as in manuf.,cturer's 
directions, ,md hybridized to a random-primer-Iabeled simian VEGF/ VPF 
cONA probc (Shima et aI, :t 996). A probe for 36B4. a ribosomc-associated 
protein (Masiakowski et aI, 1982). was used to contro l for RNA loading. 
The blot was exposed to an imaging screen and sCalmed with a Bio-Rad 
GS525 Molecular Imager systcm. The acquired image was analyzed by 
qualltifi ~a tion of the signal by volume anal)'sis (miJlim eter~ squared X pixil 
dcnsity) using the Molecular Analyst software . The numbers shown are the 
ratios of the VEGF/VPF signal divided by the signa l from the ribosomal 
protein 3 6B4 . 
RESULTS 
Uptake of Oligodeoxynucleotides in Normal Human Epi-
dermal Keratinocytes To determine the uptake of oligode-
oxynucleotides, we performed flow cytometry with FITC-ODN. 
Figure 1 shows the mean logarithmic fluorescence for untreated 
cells and ceIJs treated with FITC- ODN in the presence or absence 
of lipid . Mter 8 h , an approximate ly 12- fo ld increase in fluores-
cen ce over background in NHEKs was demonstrated, which was 
enhanced a furth er 3- to 4-fold in the presence of cation ic lipid. 
Antisense Oligodeoxynucleotides Inhibit VEGF/VPF Pro-
tein Expression in NHEKs To demonstrate an antisense effect 
on the TGF-cx induction of VEGF/VPF expression, postconfluen t 
keratinocytes were treated with Lipofectin with or without PS-
ODNs for 8 h. The medium was replaced with KJ3M in the 
presence or absence of TGF- cx. Supernatants were collected and 
assayed at 48 h after TGF-cx addition by means of a VEGF/VPF 
capture ELISA assay as described in Materials alld tHethods. Figure 
2a shows a 2.5-fold increase in VEGF/VPF expression upon 
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Table I. TGF-a-Induced VEGF/VPF Protein 
Accumulation" Is Inhibited by Antisense PS-ODN at 24 
and 48 h after Treatment 
Sample 
Untreated' 
Antisense H3 + TGF-a 
Sense H3S + TGF-a 
% VEGF (normalized to TGF-a = 100%)/' 
24 h 
41 (=5) 
54 (=10) 
108 (=17) 
48 h 
25 (=6) 
36 (=18) 
107(=11) 
~ SupenHltants assayed by ELISA in rriplkacc frOI1'1 three experiments. 
b Data arc normalized to the TGF-Ct'-induccd sa mple without PS-ODN for each time 
point and expressed as the mean :!: SO (11 = 3). 
, Without PS-ODN or TGF-<.Y. 
addition of TGF- a. Tllis induction of VEGF/VPF protein was 
inhibited by treatment of the cells with the antisense PS-ODN prior 
to TGF-a addition . Inhibition of TGF-a- induced VEGF/VPF 
expression by the antisense PS-ODN approached 100% willie the 
sense or mismatch control PS-ODNs showed little or no effect. T he 
inhibition ofVEGF/ VPF secretion by the antisense oligonucleotide 
was concentration dependent (Fig 2b). Table I summarizes the 
ELISA resu lts from three expedments . In each experiment, tile 
antisense PS-ODN (H3) inhibited the induction of VEGF/VPF 
e":pression mediated by TGF-a to near basa l levels whereas the 
control sense PS-ODN (H3S) had little or no eHect. 
VEGF/VPF mRNA Levels Decrease After Treatment with 
Antisense Oligodeoxynucleotides To determine w hether a 
decrease in VEGF/VPF protein WaS paralleled by a decrease in 
VEGF/VPF mRNA, confluent keratinocytes were treated with or 
without PS-ODNs in the presen ce of Lipofectin for 8 h , fo llowed 
by rep lacement of the medium with KBM with or without TGF-a. 
Total RNA was extracted from the ceJJs as described in }\IIaterials 
alld }\lIe/hods and examined by northern blot ana lysis. Figure 3a 
shows data analysis from a blot hybridized to a VEGF/VPF probe 
and a 36B4 probe. The results show an increase of VEGF/VPF 
RNA at 24 and 48 h in cells treated with TGF-a in the presence or 
ab sence of sense or mismatched PS-ODNs. Cells treated with the 
antisense PS-ODN showed a reduced level ofVEGF/VPF RNA to 
near-basal levels at both time points examined. T his decrease in 
VEGF/VPF RNA Icvels was paraLleled by a decrease in VEGF/VPF 
protein accumu lation in th e m edium as assayed by capture ELISA 
(Fig 3b) while treatment with the control PS-ODN showed little or 
no effect. An uncxpected decrease at 48 h with the control 
sense- treated cells at the RNA level was observed. This decrease, 
however, was 110t foHowed by a concomitant decrease in the 
VEGF/VPF protein expression . 
Maintenance of Inhibition of VEGF/VPF Protein Expres-
sion in NHEKs by Antisense Oligodeoxynucleotides Cells 
were treated with PS-ODNs and Lipofectin for 8 h in KBM 
0.03 a. 
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Figure 4. Antisense PS-ODN (H3) maintains inhibition ofTGF-a-
induced VEGF/VPF protein production over 120 h. NHEKs were 
incubated with or without 0.5 ,....M PS-ODNs, antisense (H3) or sense 
(H3S) , for 8 h in the presence ofLipofectin. The medium was replaced with 
KBM + TGF-a, and the culture supematants for each treatment were 
analyzed for VEGF/VPF by a capture ELISA after 48 h (D), 72 h C-), 96 h 
(0 ), and 120 h (.). Data are expressed as optical density (0.0 .) units at 450 
nl11 subtracting 0.0. un.its at 620 nm for background. Error !Jars, SO (n = 3). 
medium. The m edium was aspirated and replaced with KBM 
containing TGF-a .. Supernatants were collected at 48 72 96 and 
120 h after PS-ODN treatment and TGF-O:' addition 3l~d a~say~d by 
ELISA for VEGF/VPF protein. An accumulation of VEGF/VPF 
protein was noted widl increasing time of induction . The inllibitiol1 
of VEGF/VPF protein expression by PS-ODNs was maintained 
from 48 h to 120 h as shown in Fig 4. The control sense PS-ODN 
H3S sl~owed a slight stimulatory effect on VEGF/VPF protein 
ex.presslon. No loss in keratinocyte viability was observed by light 
mICroscopy during the co urse of the experiment. 
DISCUSSION 
Al1ti.sen~e therapeutics h ave been suggested for many clinical 
a~plicat1ons such as v iral infections (human immunodeficiency 
VITUS, hu.man papilloma virus, hepatitis C virus, and human cyto-
mcgalovlrus) and acute mye logenou s leukemia or m yelodysplastic 
syndrome (Fic ld and Goodchild, 1.995). Antiscnse oligonucleotides 
tar~eted to ml11;ne VEGF/VPF have recend y been shown to inhibit 
reanal neovascularization in a murine model of proliferative reti-
nopathy (Robinson e/ ai, 1996). 
In this re~ort, we identify a 19-bp antiscnse PS-ODN (H3) 
targeted agamst human VEGF/VPF that has th e ability to dOWll-
regulate TGF-O:'-induced VEGF/VPF expression in human cpider-
mal keratmocytes. Deli vel), of the PS-ODNs wid, Lipofectin was 
n ecessat)' to achieve maximal inhibition of the TGF- O:' induction of 
~GF/VPF. T he use of lipids to efficiently target oligodcoxynucle-
otldes to the nucleus and not endosom al vesicles in keratinocytes 
has been dcmonstrated previou sly (Hert! e/ ai, 1995). 
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Figure 3. Autisense PS-ODN (H3) inhib-
its VEGFNPF induction by TGF-a at the 
level of mRNA (a) and protem (/J) at 24 
and 48 h after treatment. NHEKs were 
pretreated with PS-ODNs for 8 h in the 
presence of Lipofectin and then incubated ill 
KBM with or without TGF-a for 24 or 48 h. 
0 , Untreated cells (without PS-ODN or 
TGF-a); . , + TGF-a ; D , H3 antisense + 
TGF-a; . , H3S sense + TGF- <Y. (a) Data 
obta ined fro l11 northern blot hybridized with 
VEGF/ VPF and 36B4 cDNA probes and an-
alyzed for signal intensity. T he ratio ofVEGFI 
VPF to 36B4 mRNA is shown. (IJ) ELISA data 
of conditioned medium expressed as optical 
density (0.0.) lUli ts at 450 nm subtracting 
0.0. units at 620 11m fo r background. Em)/' 
"aI's, SO (11 = 3). 
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The TGF-a-induced expression ofVEGF/VPF in normal human 
epidermal keratinocytes is an attractive model system to examine 
antisense inhibition of VEGF/VPF because it attempts to simulate 
the in vi/lo condition where the pathologic progression of psoriasis 
is associated with an elevati.on of TGF-a levels (Elder et ai, 1989, 
Detmar et ai, 1994; Watts ct aI, 1994) . This report sugges ts that 
antisense oligodeoxynucleotides may have a potential therapeutic 
role in the treatment of psoriasis. 
The possible mechanisms of action of antisense oligodem.:ynucle-
otides include inhibition of transcription or trans lation and InRNA 
degradation through an RNase 1-1 cleavage mechanism (Mirabelli 
and Crooke, 1993). In our experimental systems, a complctc 
2' O-methyl antisense oUgodem.:ynucleotide had Uttlc or no effect 
on VEGF/VPF expression, while an antisense oligodeoxynucle-
otide with five 2'O-methyl moieties at the 3' end retained inhibi-
tory activity equal to or slightly better than that of the phosphoro-
thioate molecule (data oot shown). Tlus indicates that RNase H 
may play an active role in the observed inlubition ofVEGF/VPF by 
antisense oligodeoxynucleotides. 
VEGF/VPF is a potent inducer of angiogenesis and of microvas-
cu lar permeability, and its modulation may play an important ro le 
in the pathophysiology of several inflammatory and neoplastic skin 
diseases such as psoriasis (Detmar, 1996). We have examined the 
TGF-a-mediated induction of VEGF/VPF in keratinocytes and 
determined tl1at antisense PS-ODNs are able to inlubit this induc-
ti.on to near basal levels. We suggest that by regulating the 
overexpression ofVEGF/VPF in the skin via 3n antisense oligode-
oxynucleotide, it might be . possible to inhibit the VEGF/VPF-
induced angiogenic response . A less frequent administration of the 
therapeutic antisense compound may be feasible because inlubition 
ofVEGF/VPF was maintained for up to 5 d ill /li/ro. T lus technology 
may have numerous future appUcatiol1S for skin disorders charac-
terized by enhanced angiogenesis and/or microvascular permeabil-
ity. 
We IhallN J. Tallg, lif/. Eisellberg, E. Gabbidoll, alld K. Gil jor providillg Ihe 
lec/mical expertise ilL oligollllcleolide c1Wllistl}' alld Peler R obclts, Greg Pari, alld 
Kellill ClnJTey for critical fellie", oj ,II is mnllllsCI'ipl. 
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